CO4920240A1 - Compuestos inhibidores de metaloproteasa diheterociclicos, composiciones farmaceuticas que los contienen y metodos para su utilizacion - Google Patents
Compuestos inhibidores de metaloproteasa diheterociclicos, composiciones farmaceuticas que los contienen y metodos para su utilizacionInfo
- Publication number
- CO4920240A1 CO4920240A1 CO97049501A CO97049501A CO4920240A1 CO 4920240 A1 CO4920240 A1 CO 4920240A1 CO 97049501 A CO97049501 A CO 97049501A CO 97049501 A CO97049501 A CO 97049501A CO 4920240 A1 CO4920240 A1 CO 4920240A1
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutical compositions
- metaloprotease
- dihetero
- cyclic
- methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000005741 Metalloproteases Human genes 0.000 abstract 2
- 108010006035 Metalloproteases Proteins 0.000 abstract 2
- 150000001408 amides Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000003949 imides Chemical class 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
Abstract
La presente invención se relaciona con compuestos de lafórmula o un isómero, diestereómero o enantiómero óptico del mismo, o una sal farmacéuticamente aceptable o amida biohidrolizable, éster o imida de ellos, los cuales son útiles como inhibidores de metaloproteasas.También se relaciona con composiciones farmacéuticas que comprenden una cantidad segura y efectiva de dicho compuesto y un portador farmacéuticamente aceptable, así como con un método para prevenir o tratar una enfermedad asociada con actividad indeseable de metaloproteasa a través de la administración del mencionado compuesto.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2484696P | 1996-08-28 | 1996-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO4920240A1 true CO4920240A1 (es) | 2000-05-29 |
Family
ID=21822698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO97049501A CO4920240A1 (es) | 1996-08-28 | 1997-08-27 | Compuestos inhibidores de metaloproteasa diheterociclicos, composiciones farmaceuticas que los contienen y metodos para su utilizacion |
Country Status (25)
Country | Link |
---|---|
US (2) | US6121258A (es) |
EP (1) | EP0923561B1 (es) |
JP (1) | JP3347331B2 (es) |
KR (1) | KR20000035920A (es) |
CN (1) | CN1228772A (es) |
AR (1) | AR009457A1 (es) |
AT (1) | ATE226573T1 (es) |
AU (1) | AU734834B2 (es) |
BR (1) | BR9712085A (es) |
CA (1) | CA2263917A1 (es) |
CO (1) | CO4920240A1 (es) |
CZ (1) | CZ62699A3 (es) |
DE (1) | DE69716615T2 (es) |
DK (1) | DK0923561T3 (es) |
HU (1) | HUP0000210A3 (es) |
ID (1) | ID18416A (es) |
IL (1) | IL128664A (es) |
NO (1) | NO314934B1 (es) |
NZ (1) | NZ334254A (es) |
PE (1) | PE2599A1 (es) |
PL (1) | PL331795A1 (es) |
SK (1) | SK25799A3 (es) |
TR (1) | TR199900382T2 (es) |
WO (1) | WO1998008823A1 (es) |
ZA (1) | ZA977696B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ62899A3 (cs) * | 1996-08-28 | 1999-07-14 | The Procter & Gamble Company | 1,3-Diheterocyklické metaloproteázové inhibitory |
NZ503945A (en) | 1997-07-31 | 2002-11-26 | Procter & Gamble | Metalloprotease-inhibiting amide derivatives |
HUP0101176A3 (en) | 1998-02-04 | 2002-06-28 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them |
US6410580B1 (en) | 1998-02-04 | 2002-06-25 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
US6846478B1 (en) | 1998-02-27 | 2005-01-25 | The Procter & Gamble Company | Promoting whole body health |
EA200001247A1 (ru) | 1998-06-03 | 2001-08-27 | Джи Пи Ай Нил Холдингс, Инк. | N-связанные сульфонамиды n-гетероциклических карбоновых кислот или изостеры карбоновых кислот |
US6339101B1 (en) * | 1998-08-14 | 2002-01-15 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
US6333340B1 (en) * | 1998-08-14 | 2001-12-25 | Gpi Nil Holdings, Inc. | Small molecule sulfonamides for vision and memory disorders |
US6509337B1 (en) * | 1998-09-17 | 2003-01-21 | Pfizer Inc. | Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors |
US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
US6300341B1 (en) | 1998-09-30 | 2001-10-09 | The Procter & Gamble Co. | 2-substituted heterocyclic sulfonamides |
JP2002525302A (ja) * | 1998-09-30 | 2002-08-13 | ザ、プロクター、エンド、ギャンブル、カンパニー | ケトアミド類を用いた脱毛の治療方法 |
OA11722A (en) * | 1998-12-02 | 2005-01-25 | Pfizer Prod Inc | Methods and compositions for restoring conformational stability of a protein of the p53 family. |
EP1147085B1 (en) | 1999-01-27 | 2005-11-16 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors / tnf-alpha converting enzyme (tace) inhibitors |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
AR022423A1 (es) * | 1999-01-27 | 2002-09-04 | American Cyanamid Co | Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6544984B1 (en) | 1999-01-27 | 2003-04-08 | American Cyanamid Company | 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids |
NZ513831A (en) | 1999-03-03 | 2001-09-28 | Procter & Gamble | Alkenyl- and alkynyl-containing metalloprotease inhibitors |
KR20010102485A (ko) | 1999-03-03 | 2001-11-15 | 데이비드 엠 모이어 | 디헤테로-치환된 메탈로프로테아제 저해제 |
EP1259499A1 (en) * | 2000-02-21 | 2002-11-27 | Fujisawa Pharmaceutical Co., Ltd. | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors |
US8283135B2 (en) | 2000-06-30 | 2012-10-09 | The Procter & Gamble Company | Oral care compositions containing combinations of anti-bacterial and host-response modulating agents |
DE60134854D1 (de) | 2000-06-30 | 2008-08-28 | Procter & Gamble | Orale zubereitungen, die wirtsantwortmodulierenden wirkstoffe enthalten |
JP2005500270A (ja) * | 2001-05-29 | 2005-01-06 | ギルフォード ファーマシュウティカルズ インコーポレイテッド | 手術の結果として発生した神経損傷を治療するための方法 |
BR0213736A (pt) | 2001-11-01 | 2004-10-19 | Wyeth Corp | ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace |
WO2005021489A2 (en) | 2002-12-23 | 2005-03-10 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
AU2004240629B2 (en) * | 2003-05-16 | 2010-02-25 | Arriva Pharmaceuticals, Inc. | Treatment of respiratory disease by inhalation of synthetic matrix metalloprotease inhibitors |
US20050148512A1 (en) * | 2003-11-10 | 2005-07-07 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
JP4777738B2 (ja) * | 2004-10-14 | 2011-09-21 | 株式会社 資生堂 | Adam活性阻害物質によるしわの防止または改善 |
JP2007119444A (ja) * | 2005-09-29 | 2007-05-17 | Shiseido Co Ltd | Adam阻害剤によるしわの防止または改善 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8601368D0 (en) * | 1986-01-21 | 1986-02-26 | Ici America Inc | Hydroxamic acids |
DK77487A (da) * | 1986-03-11 | 1987-09-12 | Hoffmann La Roche | Hydroxylaminderivater |
FR2609289B1 (fr) * | 1987-01-06 | 1991-03-29 | Bellon Labor Sa Roger | Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes |
GB8827305D0 (en) * | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
GB8919251D0 (en) * | 1989-08-24 | 1989-10-04 | British Bio Technology | Compounds |
DE4011172A1 (de) * | 1990-04-06 | 1991-10-10 | Degussa | Verbindungen zur bekaempfung von pflanzenkrankheiten |
US5183900A (en) * | 1990-11-21 | 1993-02-02 | Galardy Richard E | Matrix metalloprotease inhibitors |
US5189178A (en) * | 1990-11-21 | 1993-02-23 | Galardy Richard E | Matrix metalloprotease inhibitors |
GB9102635D0 (en) * | 1991-02-07 | 1991-03-27 | British Bio Technology | Compounds |
GB9107368D0 (en) * | 1991-04-08 | 1991-05-22 | Smithkline Beecham Plc | Novel compounds |
IL98681A (en) * | 1991-06-30 | 1997-06-10 | Yeda Rehovot And Dev Company L | Pharmaceutical compositions comprising hydroxamate derivatives for iron removal from mammalian cells and from pathogenic organisms and some novel hydroxamate derivatives |
DE4127842A1 (de) * | 1991-08-22 | 1993-02-25 | Rhone Poulenc Rorer Gmbh | 5-((omega)-arylalky)-2-thienyl alkansaeuren, ihre salze und/oder ihre derivate |
JPH05125029A (ja) * | 1991-11-06 | 1993-05-21 | Yamanouchi Pharmaceut Co Ltd | 新規なアミド化合物又はその塩 |
AU3899193A (en) * | 1992-04-07 | 1993-11-08 | British Bio-Technology Limited | Hydroxamic acid based collagenase and cytokine inhibitors |
WO1993021942A2 (en) * | 1992-05-01 | 1993-11-11 | British Biotech Pharmaceuticals Limited | Use of mmp inhibitors |
AU666727B2 (en) * | 1992-06-25 | 1996-02-22 | F. Hoffmann-La Roche Ag | Hydroxamic acid derivatives |
GB9215665D0 (en) * | 1992-07-23 | 1992-09-09 | British Bio Technology | Compounds |
GB9223904D0 (en) * | 1992-11-13 | 1993-01-06 | British Bio Technology | Inhibition of cytokine production |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
GB9411598D0 (en) * | 1994-06-09 | 1994-08-03 | Hoffmann La Roche | Hydroxamic acid derivatives |
DE69511089T2 (de) * | 1994-06-22 | 1999-12-16 | British Biotech Pharm | Metalloproteinase-inhibitoren |
CA2218503C (en) * | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
WO1997020824A1 (en) * | 1995-12-08 | 1997-06-12 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation |
BR9611479B1 (pt) * | 1995-11-13 | 2009-01-13 | Ácidos alfa-iminoidroxÂmicos e carboxÍlicos n-substituÍdos cÍclicos e heterocÍclicos. | |
ATE225343T1 (de) * | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
-
1997
- 1997-08-22 AU AU41530/97A patent/AU734834B2/en not_active Ceased
- 1997-08-22 CZ CZ99626A patent/CZ62699A3/cs unknown
- 1997-08-22 KR KR1019997001656A patent/KR20000035920A/ko not_active Application Discontinuation
- 1997-08-22 SK SK257-99A patent/SK25799A3/sk unknown
- 1997-08-22 DE DE69716615T patent/DE69716615T2/de not_active Expired - Fee Related
- 1997-08-22 CN CN97197544A patent/CN1228772A/zh active Pending
- 1997-08-22 PL PL97331795A patent/PL331795A1/xx unknown
- 1997-08-22 NZ NZ334254A patent/NZ334254A/xx unknown
- 1997-08-22 AT AT97939443T patent/ATE226573T1/de not_active IP Right Cessation
- 1997-08-22 EP EP97939443A patent/EP0923561B1/en not_active Expired - Lifetime
- 1997-08-22 JP JP51171398A patent/JP3347331B2/ja not_active Expired - Fee Related
- 1997-08-22 CA CA002263917A patent/CA2263917A1/en not_active Abandoned
- 1997-08-22 WO PCT/US1997/014553 patent/WO1998008823A1/en not_active Application Discontinuation
- 1997-08-22 TR TR1999/00382T patent/TR199900382T2/xx unknown
- 1997-08-22 BR BR9712085-5A patent/BR9712085A/pt unknown
- 1997-08-22 DK DK97939443T patent/DK0923561T3/da active
- 1997-08-22 HU HU0000210A patent/HUP0000210A3/hu unknown
- 1997-08-22 IL IL12866497A patent/IL128664A/xx not_active IP Right Cessation
- 1997-08-26 US US08/918,957 patent/US6121258A/en not_active Expired - Fee Related
- 1997-08-27 CO CO97049501A patent/CO4920240A1/es unknown
- 1997-08-27 ZA ZA9707696A patent/ZA977696B/xx unknown
- 1997-08-27 AR ARP970103902A patent/AR009457A1/es unknown
- 1997-08-28 ID IDP972993A patent/ID18416A/id unknown
- 1997-08-28 PE PE1997000767A patent/PE2599A1/es not_active Application Discontinuation
-
1999
- 1999-02-18 NO NO19990759A patent/NO314934B1/no not_active IP Right Cessation
-
2000
- 2000-03-01 US US09/516,726 patent/US6399598B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1228772A (zh) | 1999-09-15 |
JP2000516953A (ja) | 2000-12-19 |
BR9712085A (pt) | 2000-10-24 |
NZ334254A (en) | 2000-11-24 |
HUP0000210A3 (en) | 2001-07-30 |
NO990759L (no) | 1999-04-27 |
PL331795A1 (en) | 1999-08-02 |
US6121258A (en) | 2000-09-19 |
PE2599A1 (es) | 1999-03-03 |
IL128664A (en) | 2003-07-06 |
AR009457A1 (es) | 2000-04-26 |
SK25799A3 (en) | 1999-12-10 |
WO1998008823A1 (en) | 1998-03-05 |
KR20000035920A (ko) | 2000-06-26 |
AU4153097A (en) | 1998-03-19 |
ZA977696B (en) | 1998-02-23 |
TR199900382T2 (xx) | 1999-05-21 |
JP3347331B2 (ja) | 2002-11-20 |
CA2263917A1 (en) | 1998-03-05 |
ID18416A (id) | 1998-04-09 |
NO314934B1 (no) | 2003-06-16 |
DE69716615T2 (de) | 2003-06-18 |
EP0923561A1 (en) | 1999-06-23 |
CZ62699A3 (cs) | 1999-07-14 |
EP0923561B1 (en) | 2002-10-23 |
DK0923561T3 (da) | 2003-02-24 |
HUP0000210A2 (hu) | 2001-04-28 |
ATE226573T1 (de) | 2002-11-15 |
US6399598B1 (en) | 2002-06-04 |
IL128664A0 (en) | 2000-01-31 |
NO990759D0 (no) | 1999-02-18 |
DE69716615D1 (de) | 2002-11-28 |
AU734834B2 (en) | 2001-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO4920240A1 (es) | Compuestos inhibidores de metaloproteasa diheterociclicos, composiciones farmaceuticas que los contienen y metodos para su utilizacion | |
CO4920241A1 (es) | Compuestos inhibidores de metaloproteasas heterociclicos, composiciones farmaceuticas que los contienen y metodos para su utilizacion | |
CO4900035A1 (es) | Compuestos inhibidores de metaloproteasas 1,3-diheterocicli- cos, composiciones farmaceuticas que los contienen y metodos para utilizacion | |
CO4900036A1 (es) | Compuestos inhibidores de metaloproteasas de amina ciclica substituida composiciones farmaceuticas que los contienen y metodos para su utilizacion | |
CO4900033A1 (es) | Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas que los contienen . | |
CO4900045A1 (es) | Compuestos inhibidores de metaloproteasas espirociclicos, composiciones farmaceuticas que los contienen y metodos para su utilizacion | |
AR012264A1 (es) | Compuesto, composicion farmaceutica y metodo para obtener la composicion para prevenir o evitar una enfermedad asociada a actividad metaloproteasicaindeseada | |
CO5420196A1 (es) | Compuestos inhibidores de metaloproteasa bidentes, composi- ciones farmaceuticas que los contienne y metodos para su utilizacion | |
UY25322A1 (es) | Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis | |
RU95104885A (ru) | 1h-индол-3-глиоксиламиды, ингибирующие spla2-медируемое выделение жирных кислот, фармацевтическая композиция | |
EA200100867A1 (ru) | Сульфаматогидроксамовая кислота как ингибитор металлопротеаз | |
NO972307L (no) | Matriksmetallproteaseinhibitorer | |
NO965568L (no) | Arylsylfonamidosubstituerte hydroksaminsyrer som matriksmetalloproteinaseinhibitorer | |
EA199800943A1 (ru) | Производные мочевины и их применение в качестве ингибиторов инозин-5`-монофосфат- дегидрогеназы | |
AR002257A1 (es) | Compuesto 1h-imidazol util como agente anti-isquemico cardiaco o agente anti-hipertensivo. procedimiento para su preparacion y composicion farmaceuticaque lo contiene. | |
EA200300306A1 (ru) | Спиропиримидин-2,4,6-трионовые ингибиторы металлопротеиназы | |
AR033356A1 (es) | Compuesto que contiene una cadena lateral heterociclica, composicion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de un medicamento | |
CO5180578A1 (es) | Inhibidores de metaloproteasas dihetero substituida que son efectivos en el tratamiento de condiciones caracterizadas por la actividad excesiva de estas enzimas | |
CO5261493A1 (es) | Procedimiento y compuestos para la inhibicion de la mrp1 | |
DK0699439T3 (da) | Behandling af sygdomme forårsaget af talgkirtellidelser med acyl-CoA-cholesterolacyltransferaseinhibitorer | |
MX9306680A (es) | Compuestos de piridil-, quinolil- y naftilmetoxifenilo que inhiben la enzima lipoxigenasa y composiciones farmaceuticas que los contienen. | |
BR0109348A (pt) | Inibidores de metaloproteases n-substituìdos os quais contêm cadeias laterais carbocìclicas | |
CO5271694A1 (es) | Inhibidores beta di-sustituidos de las metaloproteasas, composiciones farmaceuticas que los contienen y procedimientos para su aplicacion | |
AR029596A1 (es) | Compuestos inhibidores de la trombina que comprenden un grupo aminoisoquinolina | |
HN1997000070A (es) | Inhibición de las metaloproteinasas de matriz por acidos 2-((1)-aroilalquil) -4-biaril-4-oxoburiticos |